Search Results

Virus that helped eradicate smallpox takes on cancer in startups dual-mechanism immunotherapy

With a little genetic engineering, the vaccine that was key in helping eradicate smallpox more than 30 years ago could also be key in curing cancer, if a young Cleveland biotech has anything to say about it. Western Oncolytics is developing a dual-mechanism therapy that combines oncolytic virus and gene therapy technologies with the hope of wiping out the ability of cancer cells to survive in the body

Cell therapy shows remarkable ability to eradicate cancer in clinical study

PUBLIC RELEASE DATE: 19-Feb-2014 Contact: Andrea Baird bairda@mskcc.org 212-639-3573 Memorial Sloan-Kettering Cancer Center NEW YORK, February 19, 2014 Investigators from Memorial Sloan Kettering Cancer Center have reported more encouraging news about one of the most exciting methods of cancer treatment today. The largest clinical study ever conducted to date of patients with advanced leukemia found that 88 percent achieved complete remissions after being treated with genetically modified versions of their own immune cells

Genetic breakthrough means birthmarks could soon be eradicated

Scientists find mutation that results in red or purple marks Breakthrough described as 'complete game changer' Condition could now be prevented in children By Nick Mcdermott PUBLISHED: 01:55 EST, 9 May 2013 | UPDATED: 03:48 EST, 9 May 2013 Genetics: Birthmarks may become a thing of the past thanks to the efforts of researchers in the U.S.

T- Cell Therapy Eradicates an Aggressive Leukemia in Two Children

PHILDELPHIA Two children with an aggressive form of childhood leukemia had a complete remission of their diseaseshowing no evidence of cancer cells in their bodiesafter treatment with a novel cell therapy that reprogrammed their immune cells to rapidly multiply and destroy leukemia cells. A research team from The Childrens Hospital of Philadelphia and the University of Pennsylvania published the case report of two pediatric patients Online First today in The New England Journal of Medicine. It will appear in the April 18 print issue.

T- cell therapy eradicates an aggressive leukemia in 2 children

Public release date: 25-Mar-2013 [ | E-mail | Share ] Contact: Holly Auer holly.auer@uphs.upenn.edu 215-200-2313 University of Pennsylvania School of Medicine Philadelphia, March 25, 2013 - Two children with an aggressive form of childhood leukemia had a complete remission of their disease-showing no evidence of cancer cells in their bodies-after treatment with a novel cell therapy that reprogrammed their immune cells to rapidly multiply and destroy leukemia cells. A research team from The Children's Hospital of Philadelphia and the University of Pennsylvania published the case report of two pediatric patients Online First today in The New England Journal of Medicine. It will appear in the April 18 print issue.

Learn How To Quickly and Permanently Eradicate Your Autoimmune Disease – Video

Learn How To Quickly and Permanently Eradicate Your Autoimmune Disease Learn How To Quickly and Permanently Eradicate Your Autoimmune Disease.

What is CRISPR/Cas9? – PMC – National Center for Biotechnology Information

Arch Dis Child Educ Pract Ed.

Biomedical Research & Longevity Society – Wikipedia

From Wikipedia, the free encyclopedia Dietary supplement company The Biomedical Research & Longevity Society, formerly the Life Extension Foundation (LEF), is a company founded in 1980 to extend the healthy human lifespan by discovering methods to control aging and eradicate disease. Along with the Life Extension Buyer's Club, which sells vitamins and supplements, the Life Extension Foundation (LEF) was headquartered in Fort Lauderdale, Florida. It also has a call center location in Las Vegas, Nevada.

African Americans – Wikipedia

Ethnic group in the United States African Americans (also referred to as Black Americans and Afro-Americans) are an ethnic group consisting of Americans with partial or total ancestry from sub-Saharan Africa.[3][4] The term "African American" generally denotes descendants of enslaved Africans who are from the United States.[5][6][7] While some Black immigrants or their children may also come to identify as African-American, the majority of first generation immigrants do not, preferring to identify with their nation of origin.[8][9] African Americans constitute the second largest racial group in the U.S. after White Americans, as well as the third largest ethnic group after Hispanic and Latino Americans.[10] Most African Americans are descendants of enslaved people within the boundaries of the present United States.[11][12] On average, African Americans are of West/Central African with some European descent; some also have Native American and other ancestry.[13] According to U.S. Census Bureau data, African immigrants generally do not self-identify as African American

How a select few people have been cured of HIV – PBS

Over the past year, news of two new people cured of HIV grabbed headlines, stirring hopeful talk of what these scientific wonders might portend for the four-decade fight against the virus. To researchers working in the HIV cure arena, these cases are inspiring because they prove it is in fact possible to eradicate this extraordinarily complex virus from the body

Propanc Biopharma Targets Pancreatic & Ovarian Cancers for PRP Clinical Studies with Combined Markets to Reach Over $14.3 Billion by 2027 -…

MELBOURNE, Australia--(BUSINESS WIRE)--Propanc Biopharma, Inc. (OTC Pink: PPCB) (Propanc or the Company), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that Chief Scientific Officer and Co-Founder, Dr Julian Kenyon, MD, MB, ChB, explains why pancreatic and ovarian cancers are selected as the primary target therapeutic indications for planned PRP human studies. According to Dr Kenyon, target indications were selected based on in vitro and in vivo data, as well as clinical observations from a compassionate use study investigating the effects of two proenzymes, trypsinogen and chymotrypsinogen against a range of malignant tumors.

Feral swine meetings Thursday in Eureka and Libby – The Western News

The discovery of a pig carcass on national forest land near Lake Koocanusa has prompted the Montana Department of Livestock, Montana Invasive Species Council, and USDA-APHIS Wildlife Services to hold public meetings about feral swine in Eureka and Libby on Thursday, Sept. 22.

PROMISING STEM CELL THERAPY IN THE MANAGEMENT OF HIV & AIDS | BTT – Dove Medical Press

Introduction Stem cells are highly specialized cell types with an impressive ability to self-renew, able to transform into one or even more specific cell types that play a significant role in the regulation and tissue healing process.17 To self-renew, a stem divides into two identical daughter stem cells and a progenitor cell and the embryonic and adult cells contain stem cells.1,2,8 Curing patients with serious medical conditions has been the focus of all disciplines of medical research for many years. Stem cell treatment has evolved into a highly exciting and progressed field of scientific research

TC BioPharm Announces Formation of Scientific Advisory Board with Renowned Cell Therapy Experts – GuruFocus.com

EDINBURGH, Scotland, May 18, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and viral indications, announced today announced the formation of a scientific advisory board (SAB) to advance its gamma-delta T cell therapy, OmnImmune, for the treatment of Acute Myeloid Leukemia (AML). "We are honored to have these remarkable and accomplished cell therapeutics and scientific leaders join TC BioPharm's Scientific Advisory Board," said Bryan Kobel, CEO of TC BioPharm

Protectionism Threatens The Climate Transition Analysis Eurasia Review – Eurasia Review

ByKen Heydon* Trade is a key multiplier in spreading the technology vital to the climate transition. But protectionist tendencies embedded in the implementation of the climate transition pose a major threat to the global trading system. Technological innovation backed by a carbon tax to make it competitive is the essential requirement for transition to net-zero carbon emissions by 2050.

Trich confirmed in Utah beef herd – Beef Magazine

The Utah State Veterinarians office has identified several cases of trichomoniasis (Trich) positive bulls from a beef cattle herd. This herd had grazed the summer of 2021 at a grazing association in southern Idaho with several other herds, including at least six herds from Utah. There are ten potentially exposed cattle herds that are awaiting test results; five herds belonging to the aforementioned grazing association and five herds that neighbor the affected properties.

Taysha Gene Therapies Announces Positive Initial Biomarker Data For TSHA-101 – BioSpace

Patient 1 with Sandhoff disease realized normalization of Hex A enzyme activity by Month 1, achieving 58-fold above the presumed asymptomatic level of 5% of normal identified by natural history at Month 3 Patient 2 with Tay-Sachs disease achieved Hex A enzyme activity 5-fold above the presumed asymptomatic level of 5% of normal identified by natural history at Month 1 First-ever data supporting bicistronic vector approach in humans, TSHA-101 is designed to deliver both HEXA and HEXB genes in the endogenous ratio Conference call and live webcast today at8:00 AM Eastern Time DALLAS--(BUSINESS WIRE)-- Taysha Gene Therapies (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today reported positive initial serum -hexosaminidase A (Hex A) enzyme activity data for TSHA-101 in patients with Sandhoff and Tay-Sachs diseases, which represent two forms of GM2 gangliosidosis. Todays data are the first ever to support the bicistronic vector approach in humans delivering both HEXA and HEXB genes in the endogenous ratio.

STAT’s guide to the next generation of CAR-T therapies – STAT

CAR-T cell therapy has been a boon for treating blood cancers. Since the technology was first brought to the clinic, CAR-T has offered patients months or years of life after they had exhausted all other treatment options and would have died within weeks. Its been incredible, said Marcela Maus, an immunologist and cell therapist at Mass General Cancer Center.

Best Skin Tag Remover Review: Top Remedy to Get Rid of Skin Tags – Enumclaw Courier-Herald

Moles and skin tags are common skin problems. They might be aggravating as well. They could turn out to be harmful at times

The market for Europe hereditary genetic testing is predicted to grow at a CAGR of 13.34% during the forecast period 2021-2031 – Yahoo Finance

Europe Hereditary Genetic Testing Market to Reach $19.

Taysha Gene Therapies Announces Sponsored Genetic Testing for Giant Axonal Neuropathy (GAN) in Partnership with GeneDx as well as a Collaboration with…

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced sponsored genetic testing for giant axonal neuropathy (GAN) in partnership with GeneDx, Inc., a leader in genomic analysis and a wholly owned subsidiary of BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK).

The five biggest threats to our natural world and how we can stop them – The Guardian

The worlds wildlife populations have plummeted by more than two-thirds since 1970 and there are no signs that this downward trend is slowing. The first phase of Cop15 talks in Kunming this week will lay the groundwork for governments to draw up a global agreement next year to halt the loss of nature. If they are to succeed, they will need to tackle what the IPBES (Intergovernmental Science-Policy Platform on Biodiversity and Ecosystem Services) has identified as the five key drivers of biodiversity loss: changes in land and sea use; direct exploitation of natural resources; climate change; pollution; and invasion of alien species

Taysha Announces Exclusive Option from UTSW to License Worldwide Rights to Clinical-Stage AAV9 Gene Therapy Program for CLN7 Disease, a Research…

CLN7 program currently in Phase 1 clinical proof-of-concept trial with preliminary data anticipated by year-end 2021 Intrathecal dosing of the high dose first-generation construct resulted in nearly complete normalization of impaired open field and motor function and more than doubled median life expectancy in MSFSD8 knockout mice; data to be presented at upcoming 17th Annual International Congress on Neuronal Ceroid Lipofuscinosis Taysha also enters into a research collaboration with UT Southwestern to develop next-generation construct for CLN7 disease, which is expected to improve potency, safety profile, packaging efficiency and manufacturability over first-generation construct Initiation of a planned pivotal CLN7 clinical trial with next-generation construct anticipated in 2022, with reference to human proof-of-concept data generated from first-generation construct Provides a grant to Batten Hope, the leading CLN7 patient advocacy group, to support patient awareness, disease education and newborn screening initiatives Estimated prevalence of CLN7 disease is 4,000 patients worldwide Taysha expected to have five clinical stage programs by year-end 2021 Webcast today at 8:00 AM Eastern Time DALLAS, October 05, 2021--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced that it has obtained an exclusive option from UT Southwestern (UTSW) to license worldwide rights to a clinical-stage AAV9 gene therapy replacement program for the treatment of CLN7 disease. The company has also entered into a research collaboration with UTSW to develop a next-generation construct for the treatment of CLN7 disease, which is expected to improve potency, safety profile, packaging efficiency and manufacturability over the first-generation construct

Taysha Gene Therapies Receives Orphan Drug Designation from the European Commission for TSHA-101 for the Treatment of Infantile GM2 Gangliosidosis -…

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced that it has been granted orphan drug designation from the European Commission for TSHA-101, an AAV9-based bicistronic gene replacement therapy in development for GM2 gangliosidosis, also called Tay-Sachs or Sandhoff disease

A revolution against cancer is unfolding and were just getting started – ZME Science

Its hard to put just one label on Aaron Ciechanover. He was awarded the Nobel Prize in Chemistry for characterizing the method that cells use to degrade and recycle proteins usingubiquitin, but his background stems from biology, and he was also trained as a medical doctor and a surgeon. When it comes to understanding the intricacies around human health, few people on Earth can claim the broad view that Ciechanover has.

Archives
-->